Vera Therapeutics, Inc. Stock Price, News & Analysis

On February 7, 2022, Vera Therapeutics announced a public offering of 4,000,000 shares of its Class A common stock, with all shares being offered by the company. The underwriters may purchase an additional 600,000 shares within a 30-day option. The offering is subject to market conditions and customary closing prerequisites. J.P. Morgan, Cowen, and Evercore ISI are managing the offering. The registration statement is filed with the SEC and is accessible online. Vera Therapeutics focuses on treatments for serious immunological diseases with candidates like atacicept and MAU868.

Vera Therapeutics announced plans to initiate a Phase 3 trial for atacicept in treating lupus nephritis (LN) following positive feedback from the FDA. The trial will assess the efficacy and safety of atacicept in patients with LN, addressing a critical need as current treatments have limited effectiveness. The trial features a 52-week treatment period, focusing on complete renal response as the primary endpoint. Vera is also advancing trials for other indications, including immunoglobulin A nephropathy (IgAN) and BK virus infections in kidney transplant patients.

Vera Therapeutics, a clinical-stage biotechnology company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, from 3:45-4:25 PM ET. CEO Marshall Fordyce will lead the presentation and engage in one-on-one investor meetings during the event, taking place virtually from January 10-13, 2022. A live audio webcast of the presentation will be available online, with a replay accessible for 30 days. The company focuses on innovative treatments for serious immunological diseases, including its lead product candidate, atacicept, targeting autoimmune disorders.

Vera Therapeutics has announced the acquisition of MAU868, a first-in-class monoclonal antibody targeting BK Virus (BKV) infections, which is a significant cause of kidney transplant failure. The transaction involves an upfront payment of $5 million and potential milestone payments totaling $7 million. Vera has also secured a $50 million credit facility with Oxford Finance to support further development. MAU868 is currently in a Phase 2 clinical trial, with results expected in mid-2022. This acquisition aligns with Vera’s strategy to enhance its pipeline for immunological diseases.

Vera Therapeutics announces the appointment of Kimball Hall to its board of directors. Hall, with over 30 years of experience in the pharmaceutical industry, is recognized for her leadership roles at Genentech and Amgen, and her current position as president of Abzena, a contract development and manufacturing organization. Her expertise in drug manufacturing and strategic development is expected to enhance Vera's objectives, particularly in advancing its lead clinical candidate, atacicept, aimed at treating serious immunological diseases.

Vera Therapeutics (Nasdaq: VERA), a biotechnology company focused on immunological diseases, announced that its CEO, Marshall Fordyce, will present at several investor conferences in November 2021. These include the Jefferies London Healthcare Conference (November 16-18) and the Evercore ISI HealthCONx (November 30 - December 2). Fordyce's presentations will discuss Vera’s lead product candidate, atacicept, aimed at treating autoimmune diseases. Replay links for all presentations will be available for 30 days on the company’s website.

Vera Therapeutics reported ongoing progress in its Phase 2a JANUS clinical trial for atacicept, showing substantial and durable reductions in serum Gd-IgA1 levels in patients with IgA nephropathy. Key highlights include a 60% reduction in Gd-IgA1 for the 75mg dose, indicating potential for renal survival benefits. Financially, Vera posted a net loss of $7.6 million for Q3 2021, with $86.2 million in cash as of September 30, 2021. The company is advancing the Phase 2b ORIGIN study and awaits FDA feedback on its lupus nephritis development strategy.

The Phase 2a JANUS clinical trial for atacicept, conducted by Vera Therapeutics, demonstrated a significant and durable reduction in serum galactose-deficient IgA1 (Gd-IgA1) over 72 weeks in patients with IgA nephropathy (IgAN). The trial revealed that atacicept 75mg lowered serum Gd-IgA1 levels to the lowest risk quartiles, highlighting its potential to improve renal survival. These findings were presented at the American Society of Nephrology Kidney Week 2021. The company anticipates further results from the ongoing Phase 2b ORIGIN trial to clarify the implications of these reductions on renal function.

Vera Therapeutics announces the upcoming presentation of clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be shared during an ePoster session at the American Society of Nephrology Kidney Week 2021, held virtually from November 4-7, 2021. The presentation, titled 'Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients', will feature critical findings aimed at advancing treatments for this immunological disease.